Estimaciones de analistas de Wall Street para Burning Rock Biotech Limited (BNR): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 3 |
| Mantener | 0 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 3 |
| Calificación media (1-5) | 1.00 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-17 | $-2.29 | ||
| 2026-09-10 | $-0.20 | $-2.29 | +91.3% |
| 2026-06-09 | $-0.20 | $-2.29 | +91.3% |
| 2026-03-12 | $-0.21 | $-1.40 | +85.0% |
| 2025-11-20 | $-0.26 | $-1.41 | +81.6% |
| 2025-09-08 | $-0.15 | $-1.49 | +89.9% |
| 2025-06-06 | $-0.17 | $-1.52 | +88.8% |
| 2025-03-25 | $-1.08 | $-1.82 | +40.6% |
Ratios de valoración
| Precio / Valor contable | 0.17 |
| EV / EBITDA | 13.42 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $111.2M | $208.9M | $381.7M | $429.9M | $507.9M | $563.2M | $537.4M | $515.8M | $539.6M |
| Coste de Ventas | $39.5M | $73.8M | $108.3M | $116.0M | $143.7M | $183.2M | $174.2M | $153.4M | $136.7M |
| Beneficio Bruto | $71.7M | $135.1M | $273.3M | $313.9M | $364.1M | $380.0M | $363.2M | $362.4M | $402.9M |
| I+D | $49.0M | $105.3M | $156.9M | $263.9M | $367.9M | $421.9M | $347.0M | $232.3M | $166.5M |
| Generales y Administrativos | $143.5M | $191.2M | $285.5M | $462.4M | $793.4M | $938.6M | $685.5M | $452.5M | $291.3M |
| Gastos Operativos | $192.6M | $296.5M | $442.4M | $726.3M | $1.16B | $1.36B | $1.03B | $720.0M | $457.8M |
| Beneficio Operativo | -$120.9M | -$161.4M | -$169.1M | -$412.4M | -$797.1M | -$980.4M | -$669.3M | -$357.6M | -$54.8M |
| EBITDA | -$99.6M | -$135.9M | -$128.8M | -$373.3M | -$746.5M | -$845.2M | -$517.9M | -$270.2M | -$32.0M |
| Gastos por Intereses | $9.9M | $18.0M | $9.0M | $667000 | $1.5M | 0 | 0 | 0 | $30000 |
| Beneficio Antes de Impuestos | -$131.3M | -$177.5M | -$169.2M | -$407.2M | -$795.8M | -$969.2M | -$651.3M | -$340.7M | -$53.8M |
| Impuestos | 0 | 0 | 0 | 0 | $899000 | $2.0M | $2.4M | $5.9M | $1.6M |
| Beneficio Neto | -$131.3M | -$177.5M | -$168.3M | -$407.2M | -$796.7M | -$971.2M | -$653.7M | -$346.6M | -$55.3M |
| BPA | $-102.02 | $-103.82 | $-142.30 | $-68.76 | $-76.45 | $-93.47 | $-63.84 | $-33.67 | $-49.60 |
| BPA Diluido | $-102.02 | $-103.82 | $-142.30 | $-68.76 | $-76.45 | $-93.47 | $-63.84 | $-33.67 | $-49.60 |
| Acciones en Circulación (Diluidas) | $1.8M | $2.2M | $2.3M | $6.9M | $10.4M | $10.4M | $10.2M | $10.3M | $1.1M |
Precio
| Precio | $12.52 |
| Capitalización | $13M |
| Bolsa | NASDAQ |
| País | CN |
Empresas relacionadas: ADVB · AEMD · ALUR · AMS · AYTU · CODX · EKSO
Explorar sector: Healthcare · Medical - Diagnostics & Research
Más secciones de BNR: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones